# Dr. Reddy’s Laboratories

> Dr. Reddy’s Laboratories is a VC fund backing Biopharma and Health Care. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hyderabad, India
- Total investments: 4
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dr--reddys-laboratories?trk=nav_account_sub_nav_company_admin
- X (Twitter): https://twitter.com/drreddys
- Website: http://www.drreddys.com/
- Facebook: https://www.facebook.com/Dr.ReddysLaboratoriesLtd

Dr. Reddy’s Laboratories is an integrated pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) businessand custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma.

## Contacts

5 contacts available for Dr. Reddy’s Laboratories. Shizune tracks 7 team members at Dr. Reddy’s Laboratories. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dr-reddys-laboratories?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 50% |
| Health Care | 2 | 50% |
| Life Science | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Series A | 1 | 25% |
| Corporate Round | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 2 | 50% |
| United States | 2 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Archana Bhaskar | Executive Vice President & Executive | 0 | https://shizune.co/investors/profile/archana-bhaskar |
| Christel Kronig | Senior Analytical Scientist | 0 | https://shizune.co/investors/profile/christel-kronig |
| Erez Israeli | Chief Executive Officer; Chief Operating Officer, Operations & Executive | 0 | https://shizune.co/investors/profile/erez-israeli |
| G.V. Prasad | Chief Executive Officer, Co-Chairman of the Board, Director & Managing Director | 0 | https://shizune.co/investors/profile/g-v-prasad |
| Marc Kikuchi | Chief Executive Officer | 0 | https://shizune.co/investors/profile/marc-kikuchi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| YouLabs | YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting healthcare for South Asians from reactive medicine to proactive prevention. the company is building a native health-data graph to establish demographic-specific clinical reference standards.Through its ultra-premium, physician-managed conciergesubscription called the 150 Programme, YouLabs delivers hyper-personalized diagnostic tracking, metabolic profiling, and custom peptide/supplement maps to high-net-worth individuals and executives via a unique WhatsApp-based AI interface. | $2.6M | Seed | Jun 12, 2026 |  |
| Coya Therapeutics | Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s proprietary CTreg (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing forserial infusions. Through our patented TAI (Tregs Against Inflammation) and EAITM (Exosomes Against Inflammation) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases. | $11.1M | Post-IPO Equity | Jan 30, 2026 |  |
| Dr Reddy’s Laboratories Russia | Dr. Reddy's Russia webpage represents the operations of Dr. Reddy's Laboratories, an international pharmaceutical company, in the Russian Federation, focusing on distributing medicines and supporting healthcare needs. The site conveys the company's commitment to delivering affordable, accessible, and innovative pharmaceuticals,driven by the principle "Good Health Can't Wait". | $65.3M | Corporate Round | Jul 25, 2025 |  |
| Perlecan Pharma | An India-based integrated drug development company. | $52.5M | Series A | Sep 30, 2005 |  |

4 of 4 investments shown.

## Co-investors
- [Citi](https://shizune.co/investors/profile/citigroup) — VC Fund, 1 deal together
- [Crane Venture Partners](https://shizune.co/investors/profile/crane-venture-partners) — VC Fund, 1 deal together
- [Greenlight Capital](https://shizune.co/investors/profile/greenlight-capital) — VC Fund, 1 deal together
- [ICICI Venture](https://shizune.co/investors/profile/icici-venture) — VC Fund, 1 deal together
- [Matrix Pharmacorp](https://shizune.co/investors/profile/matrix-pharmacorp) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Biotech Investors in India](https://shizune.co/investors/biotech-investors-india)
- [Biotech VC Funds in India](https://shizune.co/investors/biotech-vc-funds-india)
- [Biotechnology Investors in India](https://shizune.co/investors/biotechnology-investors-india)
- [Biotechnology VC Funds in India](https://shizune.co/investors/biotechnology-vc-funds-india)
- [Medical VC Funds in India](https://shizune.co/investors/medical-vc-funds-india)
- [Life Science VC Funds in India](https://shizune.co/investors/life-science-vc-funds-india)

## FAQ

### What does Dr. Reddy’s Laboratories invest in?

Dr. Reddy’s Laboratories invests primarily in Biopharma, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Dr. Reddy’s Laboratories?

Public channels for Dr. Reddy’s Laboratories include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Dr. Reddy’s Laboratories?

The team at Dr. Reddy’s Laboratories includes Archana Bhaskar (Executive Vice President & Executive), Christel Kronig (Senior Analytical Scientist) and Erez Israeli (Chief Executive Officer; Chief Operating Officer, Operations & Executive), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co